Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 39 - Medicinal preparations containing antigens or antibodies
Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248)
08/2010
08/11/2010CN101798349A Anti-uPAR humanized antibody and coding gene thereof
08/11/2010CN101798348A Anti-uPAR humanized antibody and application thereof
08/11/2010CN101798347A Monoclonal antibody for resisting high mobility group protein B1
08/11/2010CN101797390A Application of gene rabl3 antagonist and medicament containing same
08/11/2010CN101797384A Tri-union compound immunopotentiator and method for preparing same
08/11/2010CN101797383A Hydro-acupuncture preparation of monoclonal antibody
08/11/2010CN101797382A Anti-human progastrin polypeptide immune composition
08/11/2010CN101797381A Compound of hepatitis B virus antigen and lewis oligosaccharide and preparation method and application thereof
08/11/2010CN101797380A Method for preparing hogcholera vaccine
08/11/2010CN101230335B Herpes simplex virus and recombinant virus as well as host cell, and medicinal combination thereof
08/10/2010US7772386 immunization against Mycobacterium tuberculosis; purified nucleic acid molecule coding for oxidoreductase from M. tuberculosis; production of a vaccine against a virulent strain of M. tuberculosis
08/10/2010US7772375 amyloidosis; neurological disorders such as Alzheimer's Disease
08/10/2010US7772367 polypeptides that induce apoptosis of cancer cells that contain mutant p53 or over-expressed wild-type p53
08/10/2010US7772365 secreted tumor necrosis factor receptor polypeptides; modulates B cell activation; inhibiting ztnf4 activity
08/10/2010US7771998 Pharmaceutical composition for inducing an immune response in a human or animal
08/10/2010US7771980 avian cell line infected with orthomyxovirus, paramyxovirus or orthopoxvirus; smallpox, influenza, measles; useful for the mass production of vaccines
08/10/2010US7771979 Compositions and methods for generating an immune response utilizing alphavirus-based vector systems
08/10/2010US7771956 Method for detecting the presence of a phospholipid
08/10/2010US7771932 based on the determination of the simultaneous presence of the molecular group CD4, CD18 and/or CD11a, CD49b; treating an autoimmune or inflammatory disease; Crohn's disease
08/10/2010US7771931 Using presence of allelic mutation in protein kinase c gene as diagnostic indication of heart disease
08/10/2010US7771927 Multiple sclerosis-associated retroviral (MSRV) nucleic acids corresponding to the Env region
08/10/2010US7771731 immunogens; glutamine based point mutations
08/10/2010US7771730 Using immunodiagnostics to detect RNA virus infection
08/10/2010US7771729 Methods of potentiating HIV-1-specific CD8+ immune responses involving the concomitant administration of DNA and ALVAC expression vectors
08/10/2010US7771728 Hyperimmune serum-reactive antigen for use in prevention and treatment of tumor, allergen or metabolic disorders
08/10/2010US7771727 Conjugates of therapeutic or cytotoxic agents and biologically active peptides
08/10/2010US7771726 Use of synthetic glycolipids as universal adjuvants for vaccines against cancer and infectious diseases
08/10/2010US7771725 vaccine; for dengue, yellow fever, West Nile , chikungunya, Ross River, O'nyong-nyong, and Mayaro viruses
08/10/2010US7771724 Interfering with platelet adhesion by modulating the adhesion of amino acid residues at amino acid positions 560-566 of strand beta 3 of domain A1 of von Willebrand factor to amino acid residues at amino acid positions 227-242 of a region of platelet platelet-receptor glycoprotein Ib alpha (GpIb alpha)
08/10/2010US7771723 Remedies for myeloma to be used together with nitrogen mustard antitumor agents
08/10/2010US7771722 Using immunoglobulin specific for beta amyloid protein or sequestering protein to diagnose/ prognose nervous sytem disorders
08/10/2010US7771721 Methods for using chimeric vascular endothelial growth factor receptor proteins
08/10/2010US7771720 bind and neutralize Plasminogen Activator Inhibitor-1 (PAI-1) by converting PAI-1 to its latent form or increasing proteolytic cleavage; treating a fibrotic condition; inhibits accumulation of extracellular matrix (ECM)
08/10/2010US7771719 Pharmaceutical compositions, kits, and therapeutic uses of antagonist antibodies to IL-17E
08/10/2010US7771718 modulating expression of NKG2D in a lymphocyte capable of expressing NKG2D comprising binding a tumor cell produced MIC polypeptide with a monoclonal antibody; biomarker
08/10/2010US7771715 Recombinant vector expressing multiple costimulatory molecules and uses thereof
08/10/2010US7771711 Sphingolipids' polyalkylamines conjugates
08/10/2010CA2473680C Compositions and methods for the modulation of sphingolipid metabolism and/or signaling
08/10/2010CA2391507C Immunomodulatory compositions containing an immunostimulatory sequence linked to antigen and methods of use thereof
08/10/2010CA2383493C Treating prostate cancer with anti-erbb2 antibodies
08/10/2010CA2319309C Tumor-associated antigen derivatives from the mage family, and nucleic acid sequences encoding them, used for the preparation of fusion proteins and of compositions for vaccination
08/10/2010CA2253239C Antibodies against interferon alpha/beta receptor
08/10/2010CA2243235C Immunotherapy using cytotoxic t lymphocytes (ctl)
08/10/2010CA2223491C Cdr-grafted anti-tissue factor antibodies and methods of use thereof
08/10/2010CA2175567C Chimeric proteins comprising borrelia polypeptides: uses therefor
08/10/2010CA2165969C Vertebrate apoptosis gene: compositions and methods
08/05/2010WO2010088691A2 Compositions and methods for treating or preventing conditions and diseases associated with mannheimia haemolytica
08/05/2010WO2010088534A1 Methods for pancreatic tissue regeneration
08/05/2010WO2010088502A2 Insulin-like growth factor signaling and integrin
08/05/2010WO2010088498A1 Methods for treating estrogen receptor positive cancer by x-box binding protein 1 inhibition
08/05/2010WO2010088491A2 Methods of monitoring treatment of aviremic hiv-infected patients
08/05/2010WO2010088444A1 Human anti-il-6 antibodies with extended in vivo half-life and their use in treatment of oncology, autoimmune diseases and inflammatory diseases
08/05/2010WO2010088400A1 Methods of diagnosing and treating neurodegenerative diseases
08/05/2010WO2010088395A2 Novel synthetic agonists of tlr9
08/05/2010WO2010088287A1 Cobalamin taxane bioconjugates for treating eye disease
08/05/2010WO2010087972A2 Il-1 binding proteins
08/05/2010WO2010087927A2 Antibodies against and methods for producing vaccines for respiratory syncytial virus
08/05/2010WO2010087813A1 Anti-herpes simplex virus antibodies
08/05/2010WO2010087594A9 Cd93 or use of soluble fragment thereof
08/05/2010WO2010087594A2 Cd93 or use of soluble fragment thereof
08/05/2010WO2010087131A1 Hiv replication inhibitor, and use thereof
08/05/2010WO2010086854A1 Eotaxin-2 (ccl24) inhibitors in inflammatory, autoimmune, and cardiovascular disorders
08/05/2010WO2010086828A2 Agonist anti-trkb monoclonal antibodies
08/05/2010WO2010086743A2 Compositions and methods that enhance an immune response
08/05/2010WO2010086709A1 Proteinase-engineered cancer vaccine induces immune responses to prevent cancer and to systemically kill cancer cells
08/05/2010WO2010086353A1 A clostridium chauvoei polypeptide, dna encoding the polypeptide and a vaccine comprising the polypeptide
08/05/2010WO2010086189A2 Simian adenovirus nucleic acid- and amino acid-sequences, vectors containing same, and uses thereof
08/05/2010WO2010085984A1 Simian adenovirus nucleic acid- and amino acid-sequences, vectors containing same, and uses thereof
08/05/2010WO2010085896A1 Compositions comprising chlamydia antigens
08/05/2010WO2010085845A1 Cancer therapy and/or diagnosis
08/05/2010WO2010067286A3 IgE CH3 PEPTIDE VACCINE
08/05/2010WO2010066689A3 Modulators of the interaction between cholesterol molecules and the epstein-barr virus induced receptor 2
08/05/2010WO2010059969A3 Use of anti-vegf antibody in combination with chemtherapy for treating breast cancer
08/05/2010WO2010053610A3 Stable anthrax vaccine formulations
08/05/2010WO2010046474A3 Chemoattractants inhibitors and the use thereof
08/05/2010WO2010040847A3 Recombinant protein bodies as immunogen-specific adjuvants
08/05/2010WO2010040000A3 A multicomponent vaccine for malaria providing long-lasting immune responses against plasmodia
08/05/2010WO2010028093A3 Use of a truncated elf-5a1 polynucleotide to induce apoptosis in cancer cells
08/05/2010WO2010014784A3 Combination of anti-ctla4 antibody with diverse therapeutic regimens for the synergistic treatment of proliferative diseases
08/05/2010WO2010012912A3 Use of a soluble form of hla-g in the treatment of abnormal b-lymphocyte proliferation
08/05/2010WO2009148575A8 IL-1α ABS AND METHODS OF USE
08/05/2010WO2009143944A3 Treatment of thromboangiitis obliterans by removal of autoantibodies
08/05/2010WO2009082647A8 Recombinant rift valley fever (rvf) viruses and methods of use
08/05/2010WO2009059298A8 Compositions and methods of enhancing immune responses to eimeria
08/05/2010WO2009052617A9 Treatment regime for proliferative disorders
08/05/2010WO2003060149A9 Therapeutic polypeptides, nucleic acids encoding same, and methods of use
08/05/2010US20100199362 Wnt ligands involved in blood-brain barrier development and uses therefor
08/05/2010US20100197771 Influenza virus vaccine composition and methods of use
08/05/2010US20100196891 IBC-1 (Invasive Breast Cancer-1), a Putative Oncogene Amplified in Breast Cancer
08/05/2010US20100196495 Delivery of flu antibodies to surfaces in contact with air
08/05/2010US20100196491 contain at least two purified recombinant monkeypox virus proteins or peptides encoded by the open reading frames of the monkeypox ortholog genes M1R, A35R, A29L B6R, and orthologs of these proteins or peptides having 90% identity
08/05/2010US20100196477 Dry Mouldable drug formulation
08/05/2010US20100196459 Therapeutic formulations containing venom or venom anti-serum either alone or in combination for the therapeutic prophylaxis and therapy of neoplasms
08/05/2010US20100196458 Modified cytokines for use in cancer therapy
08/05/2010US20100196451 Vaccines Containing Non-Live Antigenic Vectors
08/05/2010US20100196445 Systems and methods for delivery of biologically active agents
08/05/2010US20100196441 Uses of immunologically modified scaffold for tissue prevascularization cell transplantation
08/05/2010US20100196435 Materials and methods for delivering compositions to selected tissues
08/05/2010US20100196423 soluble neutral active Hyaluronidase Glycoproteins (sHASEGPs); use treating glycosaminoglycan associated pathologies such as tumors or eye disorders; sialated and pegylated forms of a recombinant sHASEGP to enhance stability and serum pharmacokinetics over naturally occurring slaughterhouse enzymes
08/05/2010US20100196422 Novel polypeptides for isolating in vitro and preventing staphyloccocal infections on joint prostheses and other implanted foreign materials
1 ... 504 505 506 507 508 509 510 511 512 513 514 515 516 517 518 519 520 521 522 523 524 ... 1823